



BI+VICA[®]

TREATMENT DECISIONS WITH GREATER CONFIDENCE™



Forward Looking-Statements Disclaimer

The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company's business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and contingencies. Any such factors, individually or in the aggregate, may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements.


The Company, its affiliates, directors, advisors, employees and representatives expressly disclaim any liability whatsoever for such forward-looking statements. Further, forward-looking statements speak only as the date of the Investor Presentation. The Company does not undertake to update or revise the forward-looking statements that may be presented in the Investor Presentation to reflect new information, future events or for any other reason and any opinion expressed in the Investor Presentation is subject to change without notice.

Some of the financial information contained in the Investor Presentation are not directly extracted from the Company's accounting systems or records and/or are not International Financial Reporting Standards (IFRS) accounting measures. Such information has not been independently reviewed or verified by the Company's auditors. In addition, certain financial information is preliminary and has yet not been finalized or subject to review/audit from the Company's auditors. Accordingly, such preliminary financial information may change.



DiviTum[®] TKa

An early indicator of cancer treatment effectiveness




DiviTum[®] TKa cell proliferation provides quicker evaluation of cancer treatment efficacy.

Validated by a wealth of scientific evidence

30+ published and peer-reviewed articles

- ⊕ Strong evidence supporting the **use of DiviTum® TKa as a clinical biomarker** of CDK4/6i response
- ⊕ Collaboration with **world-leading academic institutions** and **KOLs**
- ⊕ **First prospective study published**


Cancer Area	Patients	Nr. of studies
Breast Cancer	3,039	14
Gastrointestinal	713	4
Malignant Melanoma	86	2
Lung Cancer	302	3
Blood Cancer	440	4
Other	457	3
Total	5,037	30



Note: Summary of clinical results available at biovica.com.

Stepwise launch plan for realizing huge potential!


BREAST CANCER




PHARMA / CDx



NEW INDICATIONS






US Sales Development

- ✓ Revenue growth is **48%** Q1 vs Q4!
- ✓ **20%** growth in ordering institutions over Q4
- ✓ **32%** new prescribers ordered DiviTum
- ✓ Both regulatory (510(k)) and reimbursement (Medicare + 6 commercial agreements) in place

IVD Tests (US)
Sales by Quarter



Moving forward – Initiatives for Accelerated Growth!



- ⊕ Grow current accounts – More prescribers from existing institutions
- ⊕ Add new accounts – Focus on IDN* and big institutions (cancer centers)
- ⊕ Facilitate ordering process – reduce administrative burden, link Biovica's LIS with customers EMR/EHR

*Integrated Delivery Networks:

Delivering both Insurance coverage and Healthcare service for the patient.
i.e. Kaiser Permanente, Sutter Health, Geisinger Health etc.



The Pharma Services & Collaboration Business

Onboarding of new biopharma customers continue according to plan

1. Service & Kit Sales

Services under TESA* or MSA**
(Multiple projects/MSA)

Value: ~500k-2.500kSEK/project

2. CDx Collaborations

CDx Development under DCA***
Collaboration fee-for-services

Value: ~50M-500M+SEK/development

3. CDx Product Sales

CDx product on the market

Value: ~500M-1.000 M SEK/year pr. product

Status (Q1 FY2024/25)

Service Work Order Book (signed):
Q1: 12.8 MSEK (Q4: 11.6MSEK)
Q1: 1 new MSA's sign. + 2 in negot.


Ongoing discussions
First pilot study running

Coming ~2026-27

*TESA: Technical Evaluation Service Agreement/Kit Sales; **MSA: Master Service Agreement; ***DCA: Development and Commercialization Agreement

Summary & Targets

- ⊕ Measures cell proliferation from a simple blood sample
- ⊕ DiviTum® TKa addresses an important clinical unmet need
- ⊕ Supported by cancer KOLs and scientific collaborators globally
- ⊕ Market potential > 2 billion USD for monitoring of metastatic cancer (key indications on key markets)



Progress made during Q1

- ⊕ US: Sales development continues – 48% up since previous quarter
- ⊕ Pharma Services: Demand for services, additional agreement signed, and new projects initiated
- ⊕ Cash-flow improved by 8 MSEK vs Q1 previous FY
- ⊕ IR: Direct issue of 16,4 + 7,5 MSEK

Targets:

- ⊕ **FY25/26**
 - Cash-flow positive 2nd half of 2025 (calendar year)
 - Goal: 35 MSEK / Q in revenues by 2nd half of 2025



BI+VICA[®]
TREATMENT DECISIONS WITH GREATER CONFIDENCE™